HUP0104000A2 - New use of taxoid derivatives - Google Patents

New use of taxoid derivatives

Info

Publication number
HUP0104000A2
HUP0104000A2 HU0104000A HUP0104000A HUP0104000A2 HU P0104000 A2 HUP0104000 A2 HU P0104000A2 HU 0104000 A HU0104000 A HU 0104000A HU P0104000 A HUP0104000 A HU P0104000A HU P0104000 A2 HUP0104000 A2 HU P0104000A2
Authority
HU
Hungary
Prior art keywords
group
formula
optionally substituted
cycloalkyl
alkynyl
Prior art date
Application number
HU0104000A
Other languages
Hungarian (hu)
Inventor
Marie-Christine Bissery
Clive Brealey
Simon Roberts
Patricia Vrignaud
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP98115650A external-priority patent/EP0982028A1/en
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of HUP0104000A2 publication Critical patent/HUP0104000A2/en
Publication of HUP0104000A3 publication Critical patent/HUP0104000A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A tal lm ny t rgya az ltal nos képletű taxoid-sz rmazékok - ahol Zhidrogénatom vagy egy ltal nos képletű csoport, amelyben R1 adottesetben szubsztitu lt benzoilcsoport vagy tenoil- vagy furoilcsoportvagy egy R2-O-CO- ltal nos képletű csoport, amelyben R2 adott esetbenszubsztitu lt alkil-, alkenil-, alkinil-, cikloalkil-, cikloalkenil-,bicikloalkil-, fenil-, naftilcsoport vagy egy arom s heterogyűrű; R3alkil-, alkenil-, alkinil-, cikloalkilcsoport, adott esetbenszubsztitu lt fenil- vagy naftilcsoport vagy egy arom s heterogyűrű;R4 és R5 egym stól függetlenül adott esetben szubsztitu lt alkoxi-,alkenil-oxi-, alkinil-oxi-, cikloalkoxi- vagy cikloalkenil-oxicsoport- új alkalmaz sa a multidrug-rezisztenci val kapcsolatos P-glikoproteint expressz ló rezisztens sejtvonalak abnorm lis szaporod snak kezelésére. Az alkalmaz s sor n egy (I) ltal nos képletű vegyületvagy gyógy szatilag elfogadható sója szolv tja hat sos mennyiségét adjk be péld ul vastagbélr k kezelésére. ÓThe substance of the invention is the taxoid derivatives of the formula - where Hydrogen atom or a group of the formula in which R1 is optionally substituted benzoyl group or thenoyl or furoyl group or a group of the formula R2-O-CO- in which R2 is given an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, phenyl, naphthyl group or an aromatic heteroring; R3 is an alkyl, alkenyl, alkynyl, cycloalkyl group, an optionally substituted phenyl or naphthyl group or an aromatic heteroring; R4 and R5 independently of each other are optionally substituted alkyloxy, alkenyloxy, alkynyloxy, cycloalkyl or cycloalkenyloxy group- a new application for the treatment of abnormal proliferation of P-glycoprotein-expressing resistant cell lines associated with multidrug resistance. In the application line, enter an effective amount of a solution of a compound of the formula (I) or a medicinally acceptable salt thereof, for example for the treatment of the colon. HE

HU0104000A 1998-08-20 1999-08-18 New use of taxoid derivatives HUP0104000A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98115650A EP0982028A1 (en) 1998-08-20 1998-08-20 New use of taxoid derivatives
US12384399P 1999-03-11 1999-03-11
PCT/EP1999/006292 WO2000010547A2 (en) 1998-08-20 1999-08-18 New use of taxoid derivatives

Publications (2)

Publication Number Publication Date
HUP0104000A2 true HUP0104000A2 (en) 2002-04-29
HUP0104000A3 HUP0104000A3 (en) 2003-01-28

Family

ID=26149552

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0104000A HUP0104000A3 (en) 1998-08-20 1999-08-18 New use of taxoid derivatives

Country Status (15)

Country Link
EP (1) EP1105119A2 (en)
JP (1) JP2002523364A (en)
KR (1) KR20010079665A (en)
CN (1) CN1313764A (en)
AU (1) AU5742099A (en)
BG (1) BG105273A (en)
CA (1) CA2341191A1 (en)
EE (1) EE200100082A (en)
HU (1) HUP0104000A3 (en)
IL (1) IL141231A0 (en)
MX (1) MXPA01001721A (en)
NO (1) NO20010655D0 (en)
SK (1) SK2352001A3 (en)
TR (1) TR200100575T2 (en)
WO (1) WO2000010547A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2922107B1 (en) * 2007-10-10 2010-02-26 Aventis Pharma Sa NEW TAXOID COMPOSITIONS
CA2779009A1 (en) 2009-10-29 2011-05-05 Aventis Pharma S.A. Novel antitumoral use of cabazitaxel

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2697522B1 (en) * 1992-10-30 1994-11-25 Rhone Poulenc Rorer Sa Process for the preparation of taxane derivatives.
MA23823A1 (en) * 1995-03-27 1996-10-01 Aventis Pharma Sa NEW TAXOIDS, THEIR PREPARATION AND THE COMPOSITIONS CONTAINING THEM
FR2732968B1 (en) * 1995-04-14 1997-05-16 Rhone Poulenc Rorer Sa NOVEL TAXOIDS, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Also Published As

Publication number Publication date
NO20010655L (en) 2001-02-07
IL141231A0 (en) 2002-03-10
SK2352001A3 (en) 2001-07-10
TR200100575T2 (en) 2001-07-23
BG105273A (en) 2001-11-30
MXPA01001721A (en) 2005-06-03
HUP0104000A3 (en) 2003-01-28
WO2000010547A2 (en) 2000-03-02
NO20010655D0 (en) 2001-02-07
CA2341191A1 (en) 2000-03-02
KR20010079665A (en) 2001-08-22
EE200100082A (en) 2002-06-17
WO2000010547A3 (en) 2000-06-29
EP1105119A2 (en) 2001-06-13
CN1313764A (en) 2001-09-19
AU5742099A (en) 2000-03-14
JP2002523364A (en) 2002-07-30

Similar Documents

Publication Publication Date Title
HUP0302044A2 (en) Association of the cb1 receptor antagonist and a sibutramin, pharmaceutical compositions containing same and use thereof for treating obesity
HUP0000434A2 (en) 1,4-substituted cyclic amine derivatives
HUP0300195A2 (en) Heterocyclic sodium/proton exchange inhibitors and pharmaceutical compositions containing them
HUP0001192A2 (en) The use of topiramate and its derivatives for the preparation of pharmaceutical compositions treating obesity
TR199903025T2 (en) 4-Phenylpiperidine beamers.
HUP0002686A2 (en) Guanidine mimics as factor xa inhibitors and pharmaceutical compositions containing the same
HUP0004150A2 (en) Indazole derivatives as tyrosine kinase receptor antagonists and pharmaceutical compositions containing them
HUP0402180A2 (en) Herbicidal substituted phenyl derivatives, preparation and use thereof
IL130659A0 (en) Phthalazinone compounds medicaments containing them and the use thereof
HUP0401488A2 (en) Fungicidal 7-amino triazolopyrimidines, preparation and use thereof and compositions containing the same
HUP0002960A2 (en) Aryloxyarylsulfonylamino hydroxamic acid derivatives
BR9509708B1 (en) endoparasiticidal compounds and compositions.
HUP0301690A2 (en) Synergistic methods and compositions for treating cancer
HUP0302067A2 (en) Guandinobenzamides, pharmaceutical compositions containing them and their use
HUP0004596A2 (en) Arylpiperazines having activity at the serotonin 1a receptor and pharmaceutical compositions containing them and their intermediates
HUP0203520A2 (en) Cosmetic or pharmaceutical composition in solid form comprising bis-acyl-amides
ATE225782T1 (en) BENZOPYRAN DERIVATIVES
HUP0001491A2 (en) Novel 1,4-diazacycloheptane derivatives and their use in hair oxidation dyes
HUP9802363A1 (en) Herbicidal sulfonamide derivatives, herbicide compositions containing these compounds as active ingredients and use thereof
HUP9802270A2 (en) Aryl glycinamide derivatives, methods of producing these substances, pharmaceutical compositions containing such compounds and their use
HUP0104657A2 (en) Imidazole compounds and pharmaceutical compositions containing them
HUP0103781A2 (en) Pharmaceutical compositions comprising atypical antiphsychotic agent in combination with acetylcholinesterase inhibitor for improving cognition
HUP0402657A2 (en) Preventives or remedies for alzheimer' s disease or amyloid protein fibrosis inhibitors containing nitrogen-containing heteroaryl compounds
HUP0100621A2 (en) Pharmaceutical compositions containing combination of a monoamine oxidase inhibitor and a h5-ht1b antagonist or partial agonist
HUP0303369A2 (en) Herbicidal composition, preparation and use thereof